As of November 14, 2026, Rallybio Corp has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from September 9, 2026 to November 4, 2026 (Form 8-K, November 4, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Rallybio Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Rallybio Corp reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-09-09 to 2026-11-04. Every row below is cited to the filing it comes from, and this page adds each new change as Rallybio Corp files it.
Layoffs on record: 1 filing or notice, latest 2024-02-06 (layoff filings and notices).
Also on the record for Rallybio Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by BALYASNY ASSET MANAGEMENT L.P. | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Cormorant Asset Management, LP | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 3.56% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G/A, by Laurion Capital Management LP | — | 5%+ stakes | Source |
| June 5, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 17.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Balyasny Asset Management L.P. | 7.12% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Cormorant Asset Management, LP | 7.56% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 5.68% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by VIKING GLOBAL INVESTORS LP | 9.99% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13D/A, by 5AM Ventures V, L.P. | — | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Laurion Capital Management LP | 5.72% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Rallybio Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Rallybio Corp and the records around it.
Rallybio Corp elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- 5AM Ventures V, L.P. also filed stake reports on 1 other company: ENTRADA THERAPEUTICS, INC. (Nov 2025)
- Johnson & Johnson also filed stake reports on 2 other companies: CVRx, Inc. (Jan 2026), Rapport Therapeutics, Inc. (Oct 2025)
- Laurion Capital Management LP also filed stake reports on 2 other companies: Pyxis Oncology, Inc. (Nov 2026), IMMUNIC, INC. (Aug 2026)
Watch Rallybio Corp
Get an email when Rallybio Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Rallybio Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Rallybio Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rallybio Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 18 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-04 | Reported | not named in the filing | 8-K, 2026-11-04 | ||
| 2026-09-09 | Reported | not named in the filing | 8-K, 2026-09-09 |
New leaders reset buying decisions — get the Full Report on Rallybio Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Rallybio Corp, with the record behind each one.
Find candidates like senior executive at Rallybio CorpEvery change, in the filing's words
Reported
2026 Equity Incentive Plan At the annual meeting of the stockholders of Rallybio Corporation ("Rallybio" or the "Company") held on November 4, 2026 (the "Annual Meeting"), the Company's stockholders considered and approved the Avenzo Therapeutics, Inc. ("Avenzo") 2026 Equity Incentive Plan (the "2026 Plan"), which will become effective on the date immediately following the consummation of the Merger (as defined below) and is contingent on the completion of the Merger.
- The 2026 Plan will be the successor to and continuation of the Rallybio Corporation 2021 Equity Incentive Plan (the "2021 Plan"), and once the 2026 Plan becomes effective, no further grants will be made under the 2021 Plan.
- Outstanding awards under the 2021 Plan will remain subject to the terms of the 2021 Plan, except to the extent they result in Returning Shares (as defined below).
- Subject to adjustment for specified changes in capitalization, the aggregate number of shares of common stock of the Company following the Merger (the "Combined Company") that may be issued pursuant to awards under the 2026 Plan will initially equal eighteen percent (18%) of the Company's common stock issued and outstanding immediately after the effective time of the Merger (the "Initial Share Reserve").
- The Initial Share Reserve consists of new shares plus up to the number of Returning Shares, as such Returning Shares become available from time to time; the number of new shares equals the Initial Share Reserve less the number of Returning Shares.
- Shares issued in connection with a merger or acquisition as permitted by applicable stock exchange listing rules, including Nasdaq Listing Rule 5635(c), will not reduce the number of shares available for issuance under the 2026 Plan.
Reported
Mr. Lieber's employment will terminate upon the closing of Rallybio's pending business combination with Avenzo Therapeutics, Inc. (Avenzo) pursuant to the Agreement and Plan of Merger and Reorganization, dated May 31, 2026, among Rallybio, Avenzo and a wholly-owned subsidiary of Rallybio, unless earlier terminated by Mr. Lieber or Rallybio.
- On September 8, 2026, Rallybio Corporation (Rallybio) announced that Jonathan Lieber, Rallybio's Chief Financial Officer, will transition to part-time employment status effective September 15, 2026 (the Employment Transition Date), but will remain Rallybio's Chief Financial Officer and Principal Financial Officer and continue to have the same duties and authority following the Employment Transition Date.
- In connection with Mr. Lieber's employment transition, he entered into an agreement (the Employment Side Letter) with Rallybio and Rallybio, LLC pursuant to which, following the Employment Transition Date, he will receive a base salary of $420,000 and be entitled to participate in Rallybio's benefit plans, but will not be entitled to receive an annual bonus for 2026 or any subsequent year during which he is employed.
Tools for this story
Each opens in a new tab, filled in for Rallybio Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
